newsfilter
← Latest News
PR Newswire·

Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026

  • Eisai & Biogen announced that lecanemab showed favorable clinical assessment results at 18 months in early Alzheimer's disease patients who were α-synuclein positive.
  • Findings from the Clarity AD CSF substudy presented at the CTAD conference indicate α-synuclein co-pathology is associated with higher amyloid burden & faster clinical decline.
  • Analysis of 623 CSF samples revealed α-synuclein pathology prevalence was 20.4% in amyloid-beta positive participants vs 10.0% in amyloid-beta negative participants.
  • α-synuclein positive participants had a mean baseline amyloid burden of 86 Centiloids compared to 67 Centiloids for α-synuclein negative participants.
  • Lecanemab demonstrated a slowing of clinical decline at Month 18 in the overall α-synuclein-tested group (n=400) & the α-synuclein positive subgroup (n=82).
  • Reduction in decline versus placebo measured by CDR-SB was 41% in the α-synuclein positive group, compared to 26% in the overall α-synuclein-tested group & 27% in the total Clarity AD population.
  • Eisai leads global development & regulatory submissions for lecanemab (LEQEMBI) while both companies co-commercialize the product.
  • Subcutaneous initiation dosing for lecanemab was approved in the U.S. in July 2026 & in China & Japan in September 2026.
Company
Eisai Inc.
Keywords
Eisai Inc.